

How a 'Regulatory Dead Zone' May Be Holding Up Copycat Insulin

January 14, 2019

ATTORNEYS

Landmon, Chad

PRACTICE AREAS

FDA

Andrew Dunn

BioPharma Dive

Axinn partner Chad Landmon was quoted in the *BioPharma Dive* article, "How a 'Regulatory Dead Zone' May Be Holding Up Copycat Insulin."

Click [here](#) to access the article.